DongKook Life Science Co Ltd
DongKook Life Science Co Ltd is a South Korean pharmaceutical company that develops and commercializes prescription drugs, primarily in the areas of oncology and rare diseases.
Business. DongKook Life Science Co Ltd (303810.KQ) is a South Korean pharmaceutical company engaged in the research, development, and sale of pharmaceutical products. The firm operates within the Healthcare sector, specifically focusing on pharmaceuticals and medical research activities. It is primarily listed on the KOSDAQ exchange. Specific details regarding operating segments or geographic revenue breakdowns are not disclosed in the available data.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
DongKook Life Science Co Ltd (303810.KQ) is a South Korean pharmaceutical company engaged in the research, development, and sale of pharmaceutical products. The firm operates within the Healthcare sector, specifically focusing on pharmaceuticals and medical research activities. It is primarily listed on the KOSDAQ exchange. Specific details regarding operating segments or geographic revenue breakdowns are not disclosed in the available data.
DongKook Life Science maintains a capital structure with a basic and diluted share count of 31,984,140 shares, indicating no immediate dilution pressure from share-based compensation or convertible instruments. The company reported free cash flow of 1,079,497,090 KRW, which suggests it is generating sufficient cash to support operations and potentially fund growth initiatives. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.
Profitability metrics show a gross profit of 7,673,328,910 KRW and operating income of 2,869,658,860 KRW, translating to a gross margin of 22.86% and an operating margin of 8.55%. These figures are below the industry median for gross margin (25.0%) and operating margin (10.0%), indicating that the company is underperforming in terms of cost control and operational efficiency.
The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to market-specific risks, particularly in South Korea, where the company is headquartered and likely derives the majority of its revenue.
Looking ahead, the company's revenue growth is expected to remain flat, with no significant changes in the current fiscal year or the next. The absence of disclosed R&D or capex plans suggests a conservative approach to growth, which may limit long-term expansion potential.
Risk factors include the inability to assess liquidity risk and the lack of disclosed capital structure details. The company has not issued any recent equity, and there is no indication of near-term dilution pressure. However, the absence of balance-sheet data limits the ability to fully evaluate financial health.
Recent filings and transcripts do not provide additional insights into the company's strategic direction or financial performance. The most recent actual revenue of 130,343,750,000 KRW and EPS of 275.00 KRW align with the latest financial snapshot, but no forward-looking guidance or material events were disclosed.
- The company generates positive free cash flow but lacks balance-sheet data to assess liquidity risk.
- Gross and operating margins are below industry medians, indicating operational inefficiencies.
- Revenue is concentrated in a single segment and geographic region, increasing exposure to market-specific risks.
- No significant growth initiatives or R&D investments are disclosed, suggesting a conservative growth strategy.
- Dilution risk is low, with no recent equity issuance or convertible instruments.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Revenue KRW 130.34B, −1,1% YoY; Operating income +9,5% YoY.
- ▍Revenue KRW 130.34B, −1,1% YoY
- ▍Operating income +9,5% YoY
- ▍Net income +285,7% YoY
- ▍Free cash flow +175,8% YoY
- ▍Net margin 6.6%
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Cash Conversion Ratiooperating_cash_flow / net_income
- Capex To Revenuecapital_expenditure / revenue
- DongKook Life Science Co Ltd Market data — financials · 2026-05-26
- DongKook Life Science Co Ltd Market data — analyst estimates · 2026-05-26